---
title: "Soft Tissue Sarcoma Case Study: Gracie Gonzales"
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
Case Study
# Soft Tissue Sarcoma Case Study: Gracie Gonzales
### After FidoCure® enabled treatment, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.
---
After FidoCure® enabled treatment, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.
Gracie, a 6-year-old spayed female American Pitbull mix, presented to her primary veterinarian after noticing pain and lameness associated with the left hind limb a few days earlier.
On physical exam a firm mass at the dorsomedial aspect of the left quadriceps muscle was appreciated around 7.5 cm in diameter. A fine needle aspirate was performed, and the cytology was found to be consistent with a soft tissue sarcoma. CBC/ Chemistry was found unremarkable, surgical excision of the mass was performed. Histopathology revealed a poorly differentiated soft tissue sarcoma with mitotic index averaging 10 per HPF and neoplastic cells extending to the surgical margins. Additional therapeutic intervention was not elected at this time.
After several months, nodules were noted at the previous surgical site indicating recurrence. Consultation with a veterinary oncologist was pursued. The oncologist noted that given the location of the mass there was not a reasonable surgical option to achieve complete resection or cryo-reduction. Staging was recommended. The presence of metastatic disease would suggest a poor prognosis with a median survival time ﹤ 4 months. Thoracic radiographs revealed multifocal pulmonary metastatic disease.
Enter FidoCure®
After consideration of all treatment options, Gracie’s family elected to enroll in FidoCure®.
Tumor tissue was sent for biopsy, as well as genomic (DNA) and transcriptomic (RNA) sequencing.
The FidoCure® analysis indicated potential for a combination approach with targeted therapies:
• Imatinib (VEGFR inhibitor)
10 mg/kg/day PO
• Trametinib (MEK/MEK2 inhibitor)
0.02 mg/kg/day PO
• Rapamycin (mTOR inhibitor)
0.1 mg/kg/day PO
Targeted therapies were prescribed by the patient’s treating veterinarian. These medications were administered orally by Gracie’s family at home. After two weeks of treatment, a third medication was introduced and subsequently discontinued due to gastroenteritis at the initial dose. The other medications were continued without side effects.
At the time of initial treatment the recurrent mass was large and firm at the proximal medial thigh, measuring approximately 7.5 cm X 7.5 cm. Two months later, the mass measured 2.5 cm X 2.5 cm. Family reported patient doing well and home with much better mobility. There was no evidence of pulmonary metastatic disease. Unremarkable thorax.
- Advanced genomic testing previously available only to humans
- A detailed report with personalized treatment options
- A FidoCure® expert always available to consult with the treating veterinarian
- Guidance on 14 precision therapies, FDA approved for humans
### Download the Case Study
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog?hsLang=en)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved